Hydromorphon Hexal

Hydromorphone, the active ingredient in Hydromorphon Hexal, is an opioid analgesic presented as an injectable solution for intravenous and subcutaneous use. It is employed to manage severe acute pain, postoperative pain, and cancer‑related pain in adult patients.

GNH USA supplies Hydromorphon Hexal as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Hydromorphon Hexal is used to treat pain conditions that involve the opioid pathway.

- Severe acute pain: provides rapid relief of intense pain episodes in adults. - Postoperative pain: helps control pain following surgical procedures. - Cancer pain: manages moderate to severe pain associated with malignant disease.

Hydromorphon Hexal may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea: feeling of sickness or urge to vomit. - Constipation: reduced bowel movements or hard stools. - Drowsiness: increased sleepiness or fatigue. - Dizziness: sensation of light‑headedness or imbalance. - Dry mouth: reduced salivation leading to a parched feeling. - Sweating: excessive perspiration unrelated to temperature.

Serious or Rare Side Effects: - Respiratory depression: slowed or shallow breathing that can be life‑threatening. - Severe hypotension: marked drop in blood pressure causing faintness. - Opioid dependence or addiction: compulsive use despite harmful consequences. - Anaphylaxis: acute allergic reaction with hives, swelling, and airway compromise. - Seizures: uncontrolled electrical activity in the brain. - Adrenal insufficiency: inadequate cortisol production leading to fatigue and weakness.

When prescribing Hydromorphon Hexal, clinicians should observe several precautionary measures to minimize risk.

Assess pain severity: confirm that opioid therapy is appropriate for the level of pain. Evaluate respiratory function: screen for existing respiratory disorders before initiation. Monitor for dependence: regularly assess patient for signs of misuse or addiction. Adjust dose in organ impairment: reduce dosage in patients with significant hepatic or renal dysfunction. Avoid use in hypersensitivity: do not administer to individuals with known allergy to hydromorphone or formulation components. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Hydromorphon Hexal can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Central nervous system depressants (e.g., benzodiazepines, barbiturates): may cause profound sedation or respiratory depression. - Monoamine oxidase inhibitors (MAOIs): risk of severe hypotension and serotonin syndrome. - Strong CYP3A4 inhibitors (e.g., ketoconazole): can increase hydromorphone plasma concentrations.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin): may reduce analgesic effect. - Serotonergic agents (e.g., SSRIs, SNRIs): potential for serotonin syndrome. - Diuretics and antihistamines: may enhance hypotensive effects.